Syndax Pharmaceuticals Inc Nonoperating Income (Expense) in USD from 2014 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Syndax Pharmaceuticals Inc quarterly/annual Nonoperating Income (Expense) history and growth rate from 2014 to Q3 2025.
  • Syndax Pharmaceuticals Inc Nonoperating Income (Expense) for the quarter ending September 30, 2025 was -$3.29M, a 160% decline year-over-year.
  • Syndax Pharmaceuticals Inc Nonoperating Income (Expense) for the twelve months ending September 30, 2025 was -$4.68M, a 119% decline year-over-year.
  • Syndax Pharmaceuticals Inc annual Nonoperating Income (Expense) for 2024 was $20.9M, a 1.55% increase from 2023.
  • Syndax Pharmaceuticals Inc annual Nonoperating Income (Expense) for 2023 was $20.6M, a 751% increase from 2022.
  • Syndax Pharmaceuticals Inc annual Nonoperating Income (Expense) for 2022 was $2.42M.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)

Syndax Pharmaceuticals Inc Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$4.68M -$3.29M -$8.74M -160% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-03
Q2 2025 $4.06M -$2.49M -$8.65M -141% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-04
Q1 2025 $12.7M -$1.09M -$8.2M -115% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-05
Q4 2024 $20.9M $2.2M -$3.24M -59.6% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-03
Q3 2024 $24.2M $5.45M +$242K +4.65% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-03
Q2 2024 $23.9M $6.15M +$1.09M +21.5% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-04
Q1 2024 $22.8M $7.11M +$2.23M +45.5% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-05
Q4 2023 $20.6M $5.43M +$3.12M +135% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-03
Q3 2023 $17.5M $5.21M +$4.95M +1888% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 $12.5M $5.06M +$4.91M +3231% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $7.62M $4.89M +$5.2M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $2.42M $2.32M +$1.87M +416% Oct 1, 2022 Dec 31, 2022 10-K 2025-03-03
Q3 2022 $552K $262K +$869K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$317K $152K +$728K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$1.05M -$311K +$249K +44.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 -$1.29M $449K +$1.01M Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 -$2.31M -$607K -$23K -3.94% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$2.28M -$576K -$124K -27.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$2.16M -$560K -$424K -312% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$1.74M -$563K -$768K -375% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-12
Q3 2020 -$967K -$584K -$904K -283% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$63K -$452K -$910K -199% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $847K -$136K -$645K -127% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q4 2019 $1.49M $205K -$291K -58.7% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-12
Q3 2019 $1.78M $320K -$183K -36.4% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-12
Q2 2019 $1.97M $458K -$105K -18.7% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-12
Q1 2019 $2.07M $509K +$156K +44.2% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-12
Q4 2018 $1.92M $496K +$111K +28.8% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-05
Q3 2018 $1.8M $503K +$145K +40.5% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-05
Q2 2018 $1.66M $563K +$360K +177% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-05
Q1 2018 $1.3M $353K +$147K +71.4% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-05
Q4 2017 $1.15M $385K +$59K +18.1% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-07
Q3 2017 $1.09M $358K +$89K +33.1% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-07
Q2 2017 $1M $203K -$73K -26.4% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-07
Q1 2017 $1.08M $206K +$1.78M Jan 1, 2017 Mar 31, 2017 10-K 2019-03-07
Q4 2016 -$706K $326K +$910K Oct 1, 2016 Dec 31, 2016 10-K 2018-03-08
Q3 2016 -$1.62M $269K +$2.14M Jul 1, 2016 Sep 30, 2016 10-K 2018-03-08
Q2 2016 -$3.76M $276K +$948K Apr 1, 2016 Jun 30, 2016 10-K 2018-03-08
Q1 2016 -$4.71M -$1.58M -$1.1M -231% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-08
Q4 2015 -$3.61M -$584K Oct 1, 2015 Dec 31, 2015 10-K 2017-03-14
Q3 2015 -$1.87M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-14
Q2 2015 -$672K Apr 1, 2015 Jun 30, 2015 10-K 2017-03-14
Q1 2015 -$477K Jan 1, 2015 Mar 31, 2015 10-K 2017-03-14

Syndax Pharmaceuticals Inc Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $20.9M +$320K +1.55% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-03
2023 $20.6M +$18.2M +751% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-03
2022 $2.42M +$3.71M Jan 1, 2022 Dec 31, 2022 10-K 2025-03-03
2021 -$1.29M +$441K +25.4% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-27
2020 -$1.74M -$3.23M -216% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 $1.49M -$423K -22.1% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
2018 $1.92M +$763K +66.2% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-12
2017 $1.15M +$1.86M Jan 1, 2017 Dec 31, 2017 10-K 2020-03-05
2016 -$706K +$2.9M +80.4% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-07
2015 -$3.61M -$5.11M -340% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-08
2014 $1.5M Jan 1, 2014 Dec 31, 2014 10-K 2017-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.